07. During his 16 years at MedImmune, it grew from a small biotechnology company into one of the five largest biotechnology companies in the world. Dr. Garland focuses on biopharmaceutical investments at NEA and is a Director of 3-V Biosciences, Cardioxyl Pharmaceuticals and Trevena, Inc. He trained in Internal Medicine and Infectious Diseases at the University of California, San Francisco. Prior to NEA, in addition to clinical practice at UCSF, Dr. Garland was with McKinsey & Company where he worked with biotechnology, pharmaceutical, medical device and diagnostics clients to evaluate investments, formulate product and corporate strategies and build businesses.
"We believe the unique Zyngenia platform has the potential to produce numerous therapeutic proteins, each with specificity for multiple targets, which may have significant advantages over both current single-specificity and bi-specific biologic drugs," said Mr. Mott. "We are excited about combining the therapeutic potential of this technology with a management team that has an impressive record of successfully building companies and developing biologics."
"It's rewarding to see my scientific technology platform coupled with the capabilities of Zyngenia's management team," said Dr. Barbas. "I look forward to working closely with the team and to leveraging the experience in biologic drug development and corporate strategy that Mr. Mott and Dr. Garland bring as we build the organization."
About Zyngenia, Inc.
Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibodies. The company uses proprietary patented technology to engineer single molecular entities that may interact with two or more targets. The company will initially focus its Zybody(TM) development on therapies for various cancers and autoimmune disorders. Zyngenia is headquartered in Rockville, Maryland. ForPage: 1 2 3 4 Related biology technology :1
. Pearl Therapeutics Raises $15.5 Million in Private Financing2
. Enobia Pharma Raises $40.1 Million Series B Financing3
. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation4
. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock5
. VisEn Medical Raises $7 Million in Series B Financing6
. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance7
. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues8
. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S9
. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance10
. Anesiva Raises $45 Million in Common Stock Offering11
. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic